Companies › Shanghai Best-Link Bioscience
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BL0175 Estrogen receptor downregulator delivered via nano-medicine formulation | ESR1 | Phase 2 | Breast Cancer (Locally Advanced or Metastatic); Breast Cancer | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07658183 | BL0175 | Phase 2 | Breast Cancer (Locally Advanced or Metastatic) | Oncology | Oct 2027 |
| NCT06738966 | BL0175 | Phase 1 | Breast Cancer | Oncology | Dec 2027 |
Atossa Therapeutics LeonaBio Olema Pharmaceuticals Shanghai Guangsheng Biopharmaceutical VIVUS
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.